Viatris (VTRS) Cash & Equivalents Growth (1y) (2020 - 2026)
Viatris (VTRS) Cash & Equivalents Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | -39.02% |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 120.45% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 12.78% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 50.32% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -32.64% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 138.97% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 37.30% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -12.11% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 59.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 138.97% |
| Dec 31, 2025 | 79.65% |
| Sep 30, 2025 | -48.09% |
| Jun 30, 2025 | -38.25% |
| Mar 31, 2025 | -25.59% |
| Dec 31, 2024 | -25.79% |
| Sep 30, 2024 | 43.46% |
| Jun 30, 2024 | 45.77% |
| Mar 31, 2024 | 100.28% |
| Dec 31, 2023 | -21.43% |
| Sep 30, 2023 | 102.51% |
| Jun 30, 2023 | -5.34% |
| Mar 31, 2023 | -32.67% |
| Dec 31, 2022 | 78.77% |
| Sep 30, 2022 | -14.53% |
| Jun 30, 2022 | -1.37% |
| Mar 31, 2022 | -6.75% |
| Dec 31, 2021 | -16.92% |
| Mar 31, 2021 | 40.97% |
| Dec 31, 2020 | 73.08% |